L’Oréal Boosts Galderma Stake to 20%, Strengthening Position in Aesthetics Market
Global beauty titan, L’Oréal, has triumphantly finalized its acquisition of an additional 10% stake in Galderma Group AG. This move escalates its total ownership to 20%, as announced on February 12, 2026. The transaction, which concluded on February 10, 2026, fortifies L’Oréal’s strategic standing in the rapidly expanding aesthetics market.
Galderma, a leader in the exclusive dermatology category, has a presence in approximately 90 countries. It operates across three key areas:
- Injectable aesthetics
- Dermatological skincare
- Therapeutic dermatology
The Swiss company is the proud owner of renowned brands such as Cetaphil, Restylane, and Dysport.
“This augmented investment reaffirms L’Oréal’s ambition to participate in the fast-growing aesthetics market,” the company expressed. The global injectable aesthetics market, valued at $9.45 billion in 2023, is projected to reach a staggering $18.12 billion by 2032. This represents a compound annual growth rate of 7.5%.
As part of the agreement, Galderma’s Board of Directors will contemplate nominating two non-independent board candidates from L’Oréal at the 2026 Annual General Meeting. These new candidates will replace representatives from the EQT-led consortium. L’Oréal CEO, Nicolas Hieronimus, emphasized, “aesthetics is a key adjacency to our core beauty business that we are keen to continue to explore.”
Source: https://www.loreal-finance.com/eng/press-release/2025-annual-results